34911880 34602832 32843476 35138577 35772726 32189390 32456064 32782777 35682137 33108240 32641376 33315629 33758644 32704554 33332928 34558336 33448127 35718364 33107349 32358796 33077615 33184044 - Search Results

Year	Number of Results
2020	9
2021	9
2022	4

1

Tubular Injury Causing Protracted Glycosuria Following Withdrawal of a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor: A Possible Role in the Development of Protracted Hypoglycemia and Ketoacidosis.

Hashi R, Fujiki N, Yagi T. Hashi R, et al. Tohoku J Exp Med. 2021 Dec;255(4):291-296. doi: 10.1620/tjem.255.291. Tohoku J Exp Med. 2021. PMID: 34911880 Free article.

2

Multicenter, Open-Label, 2-Arm, Pilot Trial for Safe Reduction of Basal Insulin Dose Combined with SGLT2 Inhibitor in Type 1 Diabetes Mellitus: Study Protocol for a RISING-STAR Trial.

Hamaguchi M, Hashimoto Y, Tanaka T, Hasegawa G, Ishii M, Okada H, Mitsuhashi K, Kitagawa N, Ushigome E, Yamazaki M, Fukui M. Hamaguchi M, et al. Clin Med Insights Endocrinol Diabetes. 2021 Sep 27;14:11795514211040539. doi: 10.1177/11795514211040539. eCollection 2021. Clin Med Insights Endocrinol Diabetes. 2021. PMID: 34602832 Free PMC article.

3

Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study.

Fralick M, Kim SC, Schneeweiss S, Everett BM, Glynn RJ, Patorno E. Fralick M, et al. BMJ. 2020 Aug 25;370:m2812. doi: 10.1136/bmj.m2812. BMJ. 2020. PMID: 32843476 Free PMC article.

4

Integrative Analysis of Randomized Clinical Trial and Observational Study Data to Inform Post-marketing Safety Decision-Making.

Lin LA, Zhang Y, Straus W, Wang W. Lin LA, et al. Ther Innov Regul Sci. 2022 May;56(3):423-432. doi: 10.1007/s43441-021-00349-x. Epub 2022 Feb 9. Ther Innov Regul Sci. 2022. PMID: 35138577 Clinical Trial.

5

Sodium-glucose cotransporter 2 inhibitors in type 1 diabetes: a missed opportunity for cardiovascular protection?

Snaith JR, Greenfield JR. Snaith JR, et al. Med J Aust. 2022 Aug 1;217(3):126-128. doi: 10.5694/mja2.51637. Epub 2022 Jun 30. Med J Aust. 2022. PMID: 35772726 No abstract available.

6

Using real-world safety data in regulatory approval decisions: Sotagliflozin and the risk of diabetic ketoacidosis.

Fralick M, Kesselheim AS. Fralick M, et al. Pharmacoepidemiol Drug Saf. 2020 Oct;29(10):1322-1324. doi: 10.1002/pds.4994. Epub 2020 Mar 18. Pharmacoepidemiol Drug Saf. 2020. PMID: 32189390 No abstract available.

7

Potential Benefits and Harms of Novel Antidiabetic Drugs During COVID-19 Crisis.

Mirabelli M, Chiefari E, Puccio L, Foti DP, Brunetti A. Mirabelli M, et al. Int J Environ Res Public Health. 2020 May 22;17(10):3664. doi: 10.3390/ijerph17103664. Int J Environ Res Public Health. 2020. PMID: 32456064 Free PMC article.

8

SGLT inhibitors in type 1 diabetes: weighing efficacy and side effects.

Janssens B, Caerels S, Mathieu C. Janssens B, et al. Ther Adv Endocrinol Metab. 2020 Jul 24;11:2042018820938545. doi: 10.1177/2042018820938545. eCollection 2020. Ther Adv Endocrinol Metab. 2020. PMID: 32782777 Free PMC article. Review.

9

Increased Risk of COVID-19 in Patients with Diabetes Mellitus-Current Challenges in Pathophysiology, Treatment and Prevention.

Gęca T, Wojtowicz K, Guzik P, Góra T. Gęca T, et al. Int J Environ Res Public Health. 2022 May 27;19(11):6555. doi: 10.3390/ijerph19116555. Int J Environ Res Public Health. 2022. PMID: 35682137 Free PMC article. Review.

10

An up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes.

Chatzopoulos G, Tziomalos K. Chatzopoulos G, et al. Expert Opin Pharmacother. 2020 Oct;21(15):1799-1803. doi: 10.1080/14656566.2020.1793961. Epub 2020 Oct 27. Expert Opin Pharmacother. 2020. PMID: 33108240 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results